desipramine has been researched along with Parkinsonian Disorders in 8 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Desipramine treatment was associated with decreased 6-(18)F-fluorodopamine-derived radioactivity in the heart, renal cortex, and thyroid gland but not in the liver, spleen, renal pelvis, or salivary glands." | 2.71 | Cardiac and extracardiac sympathetic denervation in Parkinson's disease with orthostatic hypotension and in pure autonomic failure. ( Goldstein, DS; Tipre, DN, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Simola, N | 1 |
| Serra, M | 1 |
| Marongiu, J | 1 |
| Costa, G | 1 |
| Morelli, M | 1 |
| Romuk, EB | 1 |
| Szczurek, W | 1 |
| Oleś, M | 1 |
| Gabrysiak, A | 1 |
| Skowron, M | 1 |
| Nowak, P | 1 |
| Birkner, E | 1 |
| Du, CX | 1 |
| Guo, Y | 1 |
| Zhang, QJ | 2 |
| Zhang, J | 1 |
| Lv, SX | 1 |
| Liu, J | 2 |
| Li, LB | 1 |
| Han, LN | 1 |
| Sun, YN | 1 |
| Wang, Y | 1 |
| Feng, J | 1 |
| Zhang, L | 1 |
| Wang, T | 1 |
| Chen, L | 1 |
| Dallé, E | 1 |
| Daniels, WM | 1 |
| Mabandla, MV | 1 |
| Arai, A | 1 |
| Tomiyama, M | 1 |
| Kannari, K | 1 |
| Kimura, T | 1 |
| Suzuki, C | 1 |
| Watanabe, M | 1 |
| Kawarabayashi, T | 1 |
| Shen, H | 1 |
| Shoji, M | 1 |
| Tipre, DN | 1 |
| Goldstein, DS | 1 |
| Takatsu, H | 1 |
| Wada, H | 1 |
| Maekawa, N | 1 |
| Takemura, M | 1 |
| Saito, K | 1 |
| Fujiwara, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease[NCT01676103] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for desipramine and Parkinsonian Disorders
| Article | Year |
|---|---|
Cardiac and extracardiac sympathetic denervation in Parkinson's disease with orthostatic hypotension and in pure autonomic failure.
Topics: Adult; Aged; Autonomic Nervous System; Autonomic Nervous System Diseases; Desipramine; Dopamine; Flu | 2005 |
7 other studies available for desipramine and Parkinsonian Disorders
| Article | Year |
|---|---|
Increased emissions of 50-kHz ultrasonic vocalizations in hemiparkinsonian rats repeatedly treated with dopaminomimetic drugs: A potential preclinical model for studying the affective properties of dopamine replacement therapy in Parkinson's disease.
Topics: Affect; Animals; Apomorphine; Desipramine; Disease Models, Animal; Dopamine Agents; Levodopa; Male; | 2021 |
The evaluation of the changes in enzymatic antioxidant reserves and lipid peroxidation in chosen parts of the brain in an animal model of Parkinson disease.
Topics: Animals; Antioxidants; Biomarkers; Brain; Desipramine; Disease Models, Animal; Lipid Peroxidation; M | 2017 |
Involvement of prelimbic 5-HT
Topics: Animals; Anxiety; Apomorphine; Desipramine; Disease Models, Animal; Dopamine Agents; Enzyme Inhibito | 2018 |
The theta-related firing activity of parvalbumin-positive neurons in the medial septum-diagonal band of Broca complex and their response to 5-HT1A receptor stimulation in a rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Animals; Apomorphine; Desipramine; Diagon | 2014 |
Fluvoxamine maleate normalizes striatal neuronal inflammatory cytokine activity in a Parkinsonian rat model associated with depression.
Topics: Age Factors; Animals; Animals, Newborn; Anti-Anxiety Agents; Corpus Striatum; Cytokines; Depression; | 2017 |
Reuptake of L-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter.
Topics: Animals; Antidepressive Agents, Tricyclic; Corpus Striatum; Denervation; Desipramine; Disease Models | 2008 |
Significant reduction of 125 I-meta-iodobenzylguanidine accumulation directly caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine, a toxic agent for inducing experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3-Iodobenzylguanidine; Animals; Cells, Cultured; Desip | 2002 |